Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as ...

BETHESDA, Md., April 01, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation

Related Keywords

Italy ,Spain ,Switzerland ,Swiss ,Nic Johnson ,Bristol Myers Squibb ,Elio Ambrosio ,Jonas Hannestad ,Matthias Alder ,University Of Messina ,Silverstein Foundation For Parkinson ,Michaelj Fox Foundation For Parkinson Research ,Clinical Neuroscience Research Unit ,Yale School Of Medicine ,Nasdaq ,Compensation Committee Of Gain Board Directors ,Exchange Commission On ,European Union Horizon ,Gain Therapeutics Inc ,Linkedin ,Swiss Innovation Agency ,Duke School Of Medicine ,Neuropsychiatric Institute ,Company Annual Report On Form ,Exchange Commission ,Clinical Development At Alkahest ,University Of Oviedo ,Chief Medical Officer ,Tranquis Therapeutics ,Capacity Bio ,Clinical Development ,Medical Director ,Denali Therapeutics ,Neuroscience Discovery Medicine ,Yale School ,Duke School ,Cell Biology ,Compensation Committee ,Gain Therapeutics ,Equity Incentive Plan ,Nasdaq Listing Rule ,Initial Vesting Date ,Silverstein Foundation ,Swiss Innovation ,Site Directed Enzyme Enhancement Therapy ,Private Securities Litigation Reform Act ,Annual Report ,